Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer

Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib are novel effective agents in the treatment of EGFR-driven lung cancer, but their clinical impact is often impaired by acquired drug resistance through the secondary T790M EGFR mutation. To overcome this problem, we analysed the me...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Discov
Autors principals: Li, Hongde, Stokes, William, Chater, Emily, Roy, Rajat, de Bruin, Elza, Hu, Yili, Liu, Zhigang, Smit, Egbert F, Heynen, Guus JJE, Downward, Julian, Seckl, Michael J, Wang, Yulan, Tang, Huiru, Pardo, Olivier E
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5037574/
https://ncbi.nlm.nih.gov/pubmed/27721983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/celldisc.2016.31
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars